25 September 2020 - - US-based biotechnology company Frequency Therapeutics, Inc. (NASDAQ: FREQ) has appointed Cynthia Feldmann to its board of directors, the company said.

Feldmann is an experienced finance and accounting professional who brings to Frequency several decades of experience in life sciences and public company board leadership.

She was formerly a partner at KPMG LLP, where she held leadership roles in the firm's medical technology and health care and life sciences industry groups, and was the lead partner in the life sciences practice for Coopers and Lybrand (now PricewaterhouseCoopers LLP) during her 19-year career there.

Currently, she is a member of the board of directors at STERIS PLC (NYSE: STE) and at UFP Technologies (NASDAQ: UFPT).

Feldmann has served on the STERIS board for more than fifteen years and chaired its audit committee for eight years.

She has also been a director at Atrius Health, Hanger Inc. (NYSE: HNGR), a provider of orthotic and prosthetic services and products and Heartware International, Inc., a medical device company that was acquired by Medtronic.

Frequency Therapeutics is in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.

The company's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.

The company's lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function.

In an FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed.

FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss.

The company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. (OTC: ALPMF) for FX-322, for which it retains US rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Cambridge Enterprises Ltd. (the commercialization arm of the University of Cambridge), Massachusetts Eye and Ear, Mass General Brigham and the Massachusetts Institute of Technology.